Microbiome Patents

Microbiome patents span live biotherapeutic products (LBPs); fecal microbiota transplant (FMT) formulation; defined bacterial consortia; probiotic strain IP; and microbiome diagnostics — with major activity from clinical-stage therapeutics companies; food companies; and emerging diagnostics startups: MAJOR MICROBIOME PATENT HOLDERS: SERES THERAPEUTICS: 200+; specific SER-109 (specific specific spore-based microbiome therapeutic: specific specific Firmicute spore purification from specific specific donor stool via specific specific ethanol + specific specific heat treatment for specific specific sporulation enrichment for specific specific oral administration in specific specific enteric capsule; specific specific first FDA-approved microbiome therapeutic for specific specific prevention of recurrent Clostridioides difficile infection CDI 2023); FERRING PHARMACEUTICALS: 200+; specific Rebyota (specific specific full-spectrum FMT microbiota suspension: specific specific donor stool processing via specific specific centrifugation + specific specific filtration for specific specific defined microbial community from specific specific healthy donor for specific specific rectal administration to specific specific patients with specific specific recurrent CDI; specific specific second FDA-approved FMT product 2022); VEDANTA BIOSCIENCES: 100+; specific defined bacterial consortium (specific specific rationally designed bacterial consortium VE303 of specific specific 8 non-pathogenic Clostridia strains for specific specific colonization resistance against specific specific VRE+CDI; specific specific VE202 of specific specific Clostridia for specific specific IBD); EVELO BIOSCIENCES; 4D MOLECULAR THERAPEUTICS; FINCH THERAPEUTICS: specific single-strain LBP for specific specific immune modulation; DUPONT (IFF NUTRITION); CHR. HANSEN (NOVONESIS); DANONE; NESTLÉ: 5,000+ probiotic patents each; specific probiotic strain (specific specific Lactobacillus rhamnosus GG ATCC 53103 + specific specific Bifidobacterium animalis subsp. lactis BB-12 + specific specific Lactobacillus acidophilus NCFM for specific specific specific survival in specific specific GI tract + specific specific specific adhesion to specific specific specific intestinal epithelium measured by specific specific specific Caco-2 cell adhesion assay); OPENBIOME: foundational FMT IP (non-profit stool bank); TRANSPLANT MICROBIOTA; PARENT PROJECT: disease-specific FMT for specific specific gut-brain axis.

Live biotherapeutic products (LBPs); defined bacterial consortia with known mechanisms of action; and FMT formulation innovations represent the three most commercially important and IP-active areas in microbiome therapeutics — each with distinct regulatory and patentability considerations: LIVE BIOTHERAPEUTIC PRODUCT (LBP) PATENTS: FDA REGULATORY CONTEXT: LBPs regulated as biological products (BLA pathway; 21 CFR 600–680); distinct from dietary supplements and probiotics; clinical trial requirement for indication claims; specific specific FDA 2016 LBP guidance; SPECIFIC LBP IP: specific novel bacterial strain with specific novel mechanism of action (specific specific Akkermansia muciniphila whole bacteria or specific specific outer membrane protein Amuc_1100 for specific specific intestinal epithelial barrier reinforcement via specific specific TLR2-dependent pathway measured by specific specific specific TEER transepithelial electrical resistance in specific specific specific Caco-2 monolayer with specific specific specific mucin layer culture); specific defined consortium design (specific specific top-down rational design from specific specific specific clinical isolate collection: specific specific Clostridia consortium for specific specific T-regulatory cell induction via specific specific butyrate production measured by specific specific specific mass spectrometry + specific specific specific Foxp3+ Treg enumeration by specific specific specific flow cytometry in specific specific specific specific germ-free mouse colonization model); SPORE-BASED LBP PATENTS: SERES; SPORBIOTIC: specific spore enrichment process (specific specific ethanol + specific specific heat treatment for specific specific sporulation selection from specific specific complex stool material; specific specific ethanol concentration + specific specific temperature + specific specific time parameter for specific specific maximum spore yield measured by specific specific specific CFU count after specific specific specific germination; specific specific aerobic processing enabling specific specific specific non-anaerobic clean-room manufacturing without specific specific specific full-scale anaerobic chamber requirement); FMT FORMULATION PATENTS: OPENBIOME; REBIOTIX (FERRING); CRESTOVO: specific FMT preparation (specific specific filtration: specific specific stool suspension at specific specific specific g/mL concentration through specific specific specific 0.5 mm filter for specific specific specific particle removal preserving specific specific specific microbial diversity as measured by specific specific specific 16S rRNA amplicon sequencing Shannon diversity; specific specific cryoprotectant: specific specific glycerol + specific specific skim milk for specific specific viable cell preservation during specific specific -80°C storage with specific specific measured specific CFU/mL recovery); specific rectal versus oral FMT delivery form (specific specific capsule vs. specific specific enema vs. specific specific colonoscopy for specific specific specific CDI indication with specific specific measured specific efficacy AUC).

Microbiome diagnostics; skin microbiome products; and gut-brain axis therapeutics represent three adjacent commercial markets for microbiome IP — each with distinct technical and regulatory characteristics: MICROBIOME DIAGNOSTICS PATENTS: PSOMAGEN; GENALYTE; UBIOME (DISSOLVED); ONEGEVITY (THORNE); THORNE: specific microbiome diagnostic platform (specific specific 16S rRNA V3-V4 amplicon sequencing from specific specific stool sample for specific specific genus-level relative abundance profiling; specific specific metagenomics shotgun sequencing from specific specific stool for specific specific species+functional pathway profiling from specific specific raw read assembly + specific specific HUMAnN3 pathway annotation; specific specific machine learning: specific specific random forest or specific specific XGBoost for specific specific microbiome feature → specific specific clinical endpoint prediction: specific specific IBD+IBS disease signature; specific specific colorectal cancer CRC stool microbiome diagnostic with specific specific measured AUROC on specific specific specific validated cohort); specific metabolomics-microbiome integration (specific specific stool SCFA: specific specific acetate+propionate+butyrate measurement by specific specific GC-FID as proxy for specific specific specific microbial fermentation function); SKIN MICROBIOME PATENTS: LACTOBIO (FERRING); EVELO; AOBiome; MOTHER DIRT: specific skin microbiome LBP (specific specific Roseomonas mucosa live biotherapeutic for specific specific atopic dermatitis AD: specific specific Gram-negative proteobacterium from specific specific healthy skin microbiome for specific specific S. aureus displacement; specific specific AOBiome Ammonia Oxidizing Bacteria AOB: specific specific Nitrosomonas eutropha AO1 for specific specific scalp/skin ammonia → nitrite → nitric oxide signaling pathway); specific probiotic cosmetic (specific specific lysate/heat-killed Lactobacillus for specific specific skin barrier + specific specific TLR2/4 modulation in specific specific cosmetic claim without specific specific clinical efficacy claim — patent but NOT drug); GUT-BRAIN AXIS PATENTS: CALTECH (SARKIS MAZMANIAN); PENDULUM; AXIAL BIOTHERAPEUTICS: specific gut-brain microbiome patent (specific specific Lactobacillus reuteri for specific specific oxytocin pathway in specific specific mouse model; specific specific short-chain fatty acid SCFA supplementation for specific specific specific ASD gut-brain symptom modulation); specific metabolite-mediated gut-brain signaling (specific specific serotonin biosynthesis: specific specific specific Clostridia tryptophan hydroxylase pathway contribution measured by specific specific specific 5-HT serum level vs. specific specific specific germ-free control).

Microbiome startups — operating in a sector with complex regulatory requirements; challenging product characterization; and significant IP uncertainty around naturally occurring microorganisms — must navigate a unique IP landscape: MICROBIOME STARTUP IP STRATEGY: UNDERSTAND THE MICROBIOME IP LANDSCAPE: NATURALLY OCCURRING MICROORGANISMS CANNOT BE PATENTED: Myriad Genetics (S.Ct. 2013) extended to microorganisms: naturally occurring bacterial strains = not patentable subject matter; BUT: specific isolated + specific purified strain with specific specific measurable characteristic different from its natural state + specific non-natural growth condition = patentable (specific specific specific manufacturing process makes it distinct from naturally occurring form); specific novel isolated strain from specific specific specific non-obvious environmental source with specific specific measurably different characteristic from specific specific closely related prior-art strain = composition of matter patentable if markedly different; FDA LBP REGULATORY PATHWAY AS IP MOAT: BLA/INV regulatory approval for specific indication = 12 years regulatory exclusivity for biological products + specific specific specific data exclusivity; more valuable than patent for specific indication; WHEN TO PATENT IN MICROBIOME: SPECIFIC NOVEL ISOLATE WITH MARKEDLY DIFFERENT CHARACTERISTIC: specific specific novel bacterial strain (specific specific 16S rRNA gene sequence identity to specific specific type strain) from specific specific non-obvious source with specific specific measurably different characteristic (specific specific specific growth rate + specific specific specific SCFA production profile + specific specific specific adhesion to specific specific specific intestinal cell line) not shown in prior art; SPECIFIC NOVEL CONSORTIUM DESIGN: specific novel defined bacterial consortium with specific specific rationally designed member selection + specific specific specific mechanism of action (specific specific measured Foxp3+ Treg induction + specific specific specific butyrate production in specific specific specific germ-free mouse model vs. specific specific specific single-strain control); SPECIFIC NOVEL FORMULATION: specific novel spore purification process with specific specific specific measured spore purity + specific specific specific viability after specific specific specific cryopreservation + specific specific specific stability at specific specific specific temperature; SPECIFIC NOVEL DIAGNOSTIC ALGORITHM: specific specific specific machine learning model using specific specific specific microbiome signature features for specific specific specific indication prediction with specific specific specific measured AUROC on specific specific specific validated cohort; TRADE SECRETS: specific strain biobank with specific specific culture collection; specific specific specific FMT donor selection criteria; specific specific specific consortium manufacturing process; KEY FTO: Seres Therapeutics SER-109 spore enrichment + spore-based LBP; Ferring Rebyota full-spectrum FMT filtration process; Vedanta VE303/VE202 defined Clostridia consortium; OpenBiome foundational FMT process IP; Chr. Hansen/Novonesis specific Lactobacillus + Bifidobacterium probiotic strain collection.